XASX
EYE
Market cap21mUSD
Jul 10, Last price
0.12AUD
1D
4.55%
1Q
-4.17%
Jan 2017
-91.79%
Name
Nova Eye Medical Ltd
Chart & Performance
P/E
—
P/S
1.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.90%
Rev. gr., 5y
18.04%
Revenues
29m
+25.47%
Net income
-9m
L+3.06%
CFO
-6m
L-21.73%
Dividend
Jul 21, 20200.41384 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Kent Town, Australia, and established in 1985, Nova Eye Medical Limited is dedicated to the development, manufacturing, and global commercialization of surgical solutions for eye conditions, with a primary focus on glaucoma. Their product lineup features the iTrack surgical system, engineered to reduce intraocular pressure in adult patients with open-angle glaucoma, alongside its evolution, iTrack Advance, which promotes natural ocular fluid drainage. For individuals with severe or intricate forms of glaucoma, they provide the Molteno3 drainage device. Additionally, the company offers 2RT, a unique laser technology aimed at treating early to intermediate age-related macular degeneration. Nova Eye Medical Limited maintains a significant international footprint, conducting operations across Australia, the United States, Europe, and the Asia Pacific region. The company officially adopted its current name in July 2020, having previously operated as Ellex Medical Lasers Limited.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||